AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25361836 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression (by independent review)
Number of subjects: 0
Study 25361836 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression (by investigator assessment)
Number of subjects: 0
Study 25361836 — intervention group
Group type: COMPARATOR
Intervention: Patients without progression
Number of subjects: 0
Study 22564362 — intervention group
Group type: EXPERIMENTAL
Intervention: Social isolation prevention program (4 sessions, group-based)
Number of subjects: 63
Study 22564362 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 63
Study 20932411 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrorelix pamoate 60 mg followed by 30 mg after 2 weeks
Number of subjects: 0
Study 20932411 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrorelix pamoate (various dosages: 30 + 30 mg, 30 + 30 + 30 mg, 60 + 30 mg, 60 + 60 mg)
Number of subjects: 0
Study 20932411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17902131 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified double perfusion (MDP) technique
Number of subjects: 35
Study 17902131 — intervention group
Group type: COMPARATOR
Intervention: Single aortic perfusion (SAP) technique
Number of subjects: 35
Study 15618380 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiography plus immediate MR imaging
Number of subjects: 189
Study 15618380 — intervention group
Group type: COMPARATOR
Intervention: Radiography only
Number of subjects: 189
Study 12386644 — intervention group
Group type: EXPERIMENTAL
Intervention: High-profile infusion (total dose of rilmenidine, 3.3 mg)
Number of subjects: 0
Study 12386644 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-profile infusion (total dose of rilmenidine, 1.45 mg)
Number of subjects: 0
Study 12386644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10429007 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotton swab technique
Number of subjects: 50
Study 10429007 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotton swab technique (immediate plating)
Number of subjects: 50
Study 10429007 — intervention group
Group type: COMPARATOR
Intervention: Cotton swab technique (transported samples)
Number of subjects: 50
Study 7748969 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/kg loading dose (LD) of gentamicin
Number of subjects: 26
Study 7748969 — intervention group
Group type: COMPARATOR
Intervention: 2.5 mg/kg every 12, 18 or 24 h (control group)
Number of subjects: 26
Study 1987948 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8% sezolamide hydrochloride (MK-417)
Number of subjects: 48
Study 1987948 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% MK-927
Number of subjects: 48
Study 1987948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 6849145 — intervention group
Group type: EXPERIMENTAL
Intervention: Low spinal anaesthesia using hyperbaric cinchocaine (Nupercaine; Ciba) 0.25% combined with local anaesthetic abdominal wall infiltration
Number of subjects: 0
Study 29792556 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii training plus usual care
Number of subjects: 40
Study 29792556 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 40
Study 30525258 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated partial breast irradiation (APBI)
Number of subjects: 0
Study 30525258 — intervention group
Group type: COMPARATOR
Intervention: Whole breast irradiation (WBI)
Number of subjects: 0
Study 30033879 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin oral supplementation (600 mg/day, Brai‐noil) for 6 months (Group B)
Number of subjects: 0
Study 30033879 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months followed by Curcumin (Group A)
Number of subjects: 0
Study 27102321 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise program
Number of subjects: 87
Study 27102321 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based exercise program
Number of subjects: 87
Study 27102321 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 87
Study 25101637 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture (REAL)
Number of subjects: 20
Study 25101637 — intervention group
Group type: COMPARATOR
Intervention: Phantom acupuncture (PHNT)
Number of subjects: 20
Study 22367417 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram plus paliperidone (20 mg/day + 3 mg/day)
Number of subjects: 60
Study 22367417 — intervention group
Group type: COMPARATOR
Intervention: Citalopram (20 mg/day)
Number of subjects: 60
Study 22367417 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram plus paliperidone
Number of subjects: 60
Study 22367417 — intervention group
Group type: COMPARATOR
Intervention: Citalopram
Number of subjects: 60
Study 19653176 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial approach (group I; n = 50)
Number of subjects: 100
Study 19653176 — intervention group
Group type: COMPARATOR
Intervention: Transfemoral approach (group II; n = 50)
Number of subjects: 100
Study 17451796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 17451796 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 55
Study 15924781 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg/d
Number of subjects: 108
Study 15924781 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg/d
Number of subjects: 108
Study 15924781 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 108
Study 15924781 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (both dosages)
Number of subjects: 108
Study 11952433 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion rate of 1.0 ml/s
Number of subjects: 30
Study 11952433 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion rate of 0.2 ml/s
Number of subjects: 30
Study 9593390 — intervention group
Group type: EXPERIMENTAL
Intervention: Marcus Gunn test
Number of subjects: 14
Study 9593390 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating light test
Number of subjects: 14
Study 7542473 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus interferon (IFN) at a dosage of 5.0 MU three times weekly during the first year
Number of subjects: 103
Study 7542473 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 103
Study 7542473 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus interferon (IFN)
Number of subjects: 103
Study 7542473 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 103
Study 2093956 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly interruption digoxin dosage (2 days interruption per week)
Number of subjects: 14
Study 2093956 — intervention group
Group type: COMPARATOR
Intervention: Continuous digoxin dosage (uninterrupted)
Number of subjects: 14
Study 2093956 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both dosages
Number of subjects: 14
Study 444354 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnarizine (75 mg) in capsule form
Number of subjects: 12
Study 444354 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnarizine (75 mg) in tablet form
Number of subjects: 12
Study 444354 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnarizine (75 mg)
Number of subjects: 12
Study 30602032 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg every 6 months
Number of subjects: 340
Study 30602032 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg every 3 months
Number of subjects: 340
Study 30602032 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg every 2 months
Number of subjects: 340
Study 30602032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340
Study 28936792 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha/Theta neurofeedback training (NFG)
Number of subjects: 44
Study 28936792 — intervention group
Group type: COMPARATOR
Intervention: Waiting list group (WLG)
Number of subjects: 44
Study 26430694 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1000 mg/day, four doses of 625 mg calcium carbonate for 1 month)
Number of subjects: 75
Study 26430694 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dextrose)
Number of subjects: 75
Study 24219374 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-fortified flavored skim milk (500 mL/day)
Number of subjects: 109
Study 24219374 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron and vitamin D-fortified flavored skim milk (500 mL/day)
Number of subjects: 109
Study 22517917 — intervention group
Group type: EXPERIMENTAL
Intervention: SPARX (computerised cognitive behavioural therapy)
Number of subjects: 187
Study 22517917 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (face to face counselling)
Number of subjects: 187
Study 22517917 — intervention group
Group type: EXPERIMENTAL
Intervention: SPARX
Number of subjects: 187
Study 22517917 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 187
Study 19786600 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole
Number of subjects: 0
Study 19786600 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 0
Study 19786600 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 0
Study 19786600 — intervention group
Group type: COMPARATOR
Intervention: C. glabrata
Number of subjects: 0
Study 19786600 — intervention group
Group type: COMPARATOR
Intervention: Overall breakthrough infections
Number of subjects: 0
Study 17515289 — intervention group
Group type: EXPERIMENTAL
Intervention: Emiphage (test)
Number of subjects: 24
Study 17515289 — intervention group
Group type: COMPARATOR
Intervention: Commercially available original preparation (reference)
Number of subjects: 24
Study 15510930 — intervention group
Group type: EXPERIMENTAL
Intervention: Premelle (Premarin 0.625 mg plus medroxyprogesterone acetate 2.5 mg/tablet orally)
Number of subjects: 66
Study 15510930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 11394593 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous bone‐patellar tendon‐bone graft (group 1)
Number of subjects: 102
Study 11394593 — intervention group
Group type: EXPERIMENTAL
Intervention: Semitendinosus and gracilis tendon graft reconstruction combined with an extraarticular procedure (group 2)
Number of subjects: 102
Study 11394593 — intervention group
Group type: COMPARATOR
Intervention: Semitendinosus and gracilis tendon graft reconstruction alone (group 3)
Number of subjects: 102
Study 11394593 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall knee rating
Number of subjects: 102
Study 10399111 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizolastine 10 mg daily
Number of subjects: 256
Study 10399111 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study 8301442 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 ml/kg surfactant
Number of subjects: 281
Study 8301442 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 ml/kg surfactant
Number of subjects: 281
Study 8301442 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 ml/kg surfactant
Number of subjects: 281
Study 8301442 — intervention group
Group type: COMPARATOR
Intervention: Air placebo (5.0 ml/kg)
Number of subjects: 281
Study 8301442 — intervention group
Group type: EXPERIMENTAL
Intervention: All dosage groups
Number of subjects: 281
Study 8301442 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 and 7.5 ml/kg surfactant
Number of subjects: 281
Study 8301442 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard two 5.0 ml/kg rescue doses
Number of subjects: 281
Study 3132868 — intervention group
Group type: EXPERIMENTAL
Intervention: NTG solution (2 mg/3 ml) intranasally
Number of subjects: 30
Study 3132868 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (3 ml) intranasally
Number of subjects: 30
Study 31828504 — intervention group
Group type: EXPERIMENTAL
Intervention: Low recruiters (recruitment rate below median)
Number of subjects: 15991
Study 31828504 — intervention group
Group type: COMPARATOR
Intervention: High recruiters (recruitment rate above median)
Number of subjects: 15991
Study 31828504 — intervention group
Group type: COMPARATOR
Intervention: Patients who withdrew consent (incomplete follow-up)
Number of subjects: 15991
Study 30089410 — intervention group
Group type: EXPERIMENTAL
Intervention: Carnosine supplementation (500 mg daily for two months)
Number of subjects: 36
Study 30089410 — intervention group
Group type: COMPARATOR
Intervention: Placebo (500 mg daily for two months)
Number of subjects: 36
Study 28471913 — intervention group
Group type: EXPERIMENTAL
Intervention: In-line digestive cartridge (Relizorb)
Number of subjects: 0
Study 25439118 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural self‐controlled analgesia (EA group, n = 26)
Number of subjects: 50
Study 25439118 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural self‐controlled analgesia (EA group)
Number of subjects: 50
Study 25439118 — intervention group
Group type: COMPARATOR
Intervention: Intravenous self‐controlled analgesia (IA group, n = 24)
Number of subjects: 50
Study 25439118 — intervention group
Group type: COMPARATOR
Intervention: Intravenous self‐controlled analgesia (IA group)
Number of subjects: 50
Study 22843044 — intervention group
Group type: EXPERIMENTAL
Intervention: Kettlebell training (3 times a week for 8 weeks)
Number of subjects: 40
Study 22843044 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 21993032 — intervention group
Group type: EXPERIMENTAL
Intervention: Static passive stretching (P)
Number of subjects: 49
Study 21993032 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation (PNF)
Number of subjects: 49
Study 21993032 — intervention group
Group type: EXPERIMENTAL
Intervention: Static active stretching in active tension (AT)
Number of subjects: 49
Study 21993032 — intervention group
Group type: EXPERIMENTAL
Intervention: Static active stretching in passive tension (PT)
Number of subjects: 49
Study 21993032 — intervention group
Group type: COMPARATOR
Intervention: No stretching (NS)
Number of subjects: 49
Study 19168918 — intervention group
Group type: EXPERIMENTAL
Intervention: Jumping (n = 61)
Number of subjects: 112
Study 19168918 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition (n = 9)
Number of subjects: 112
Study 19168918 — intervention group
Group type: EXPERIMENTAL
Intervention: Jumping plus Nutrition (n = 14)
Number of subjects: 112
Study 19168918 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 28)
Number of subjects: 112
Study 16600463 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular two‐implant overdentures
Number of subjects: 140
Study 16600463 — intervention group
Group type: COMPARATOR
Intervention: Conventional dentures
Number of subjects: 140
Study 12645832 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg 1.8-cineol t.i.d.
Number of subjects: 32
Study 12645832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 10752099 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult spondylolisthesis patients
Number of subjects: 150
Study 10752099 — intervention group
Group type: COMPARATOR
Intervention: Chronic low back pain patients
Number of subjects: 150
Study 10752099 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with nonorganic pain drawing
Number of subjects: 150
Study 9350554 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic scalers + prophy cups
Number of subjects: 12
Study 9350554 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic scalers + prophy cups + dental floss
Number of subjects: 12
Study 9350554 — intervention group
Group type: EXPERIMENTAL
Intervention: Gracey curettes + prophy cups
Number of subjects: 12
Study 8457308 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for cupulolithiasis
Number of subjects: 60
Study 8457308 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for canalithiasis
Number of subjects: 60
Study 3089490 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline
Number of subjects: 25
Study 3089490 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline
Number of subjects: 25
Study 29330911 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased arterial stiffness measured by pulse wave velocity (PWV)
Number of subjects: 262
Study 29330911 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased osteoprotegerin (OPG) plasma levels
Number of subjects: 262
Study 29330911 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse wave velocity (PWV) as a predictor of major adverse cardiovascular events (MACE)
Number of subjects: 262
Study 26820653 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 39
Study 26820653 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 39
Study 25547247 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Number of subjects: 100
Study 22459636 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional health promotion program for employees
Number of subjects: 320
Study 22459636 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated consumer program
Number of subjects: 320
Study 22459636 — intervention group
Group type: COMPARATOR
Intervention: Control program
Number of subjects: 320
Study 20073074 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma knife dissection
Number of subjects: 40
Study 20073074 — intervention group
Group type: COMPARATOR
Intervention: Bipolar electrocautery with cold knife
Number of subjects: 40
Study 20073074 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma knife parotidectomy
Number of subjects: 40
Study 18929612 — intervention group
Group type: EXPERIMENTAL
Intervention: High-SPQ group during letter VFT
Number of subjects: 32
Study 18929612 — intervention group
Group type: COMPARATOR
Intervention: Low-SPQ group during letter VFT
Number of subjects: 32
Study 18929612 — intervention group
Group type: EXPERIMENTAL
Intervention: High-SPQ group during category VFT
Number of subjects: 32
Study 18929612 — intervention group
Group type: COMPARATOR
Intervention: Low-SPQ group during category VFT
Number of subjects: 32
Study 17135854 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention cohort (n = 67) with systematic reminders to PCPs and cardiologists regarding lipid goals and therapeutic options.
Number of subjects: 245
Study 17135854 — intervention group
Group type: COMPARATOR
Intervention: Control cohort (n = 178) without systematic reminders.
Number of subjects: 245
Study 17135854 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention cohort (n = 67) with lipid medication change during CR.
Number of subjects: 245
Study 17135854 — intervention group
Group type: COMPARATOR
Intervention: Control cohort (n = 178) with lipid medication change during CR.
Number of subjects: 245
Study 12627040 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein with a medium dose of isoflavones (42 mg/day)
Number of subjects: 241
Study 12627040 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein with a higher dose of isoflavones (58 mg/day)
Number of subjects: 241
Study 12627040 — intervention group
Group type: COMPARATOR
Intervention: Isoflavone extracted soy protein (control)
Number of subjects: 241
Study 10834771 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxious children
Number of subjects: 0
Study 10834771 — intervention group
Group type: COMPARATOR
Intervention: Clinical control group
Number of subjects: 0
Study 10834771 — intervention group
Group type: COMPARATOR
Intervention: Normal control group
Number of subjects: 0
Study 9086005 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, high-carbohydrate diet (mean 21% of calories from fat, 61% of calories from carbohydrates)
Number of subjects: 817
Study 9086005 — intervention group
Group type: COMPARATOR
Intervention: Control group (mean 32% of calories from fat, 50% of calories from carbohydrates)
Number of subjects: 817
Study 9086005 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, high-carbohydrate diet
Number of subjects: 817
Study 1586360 — intervention group
Group type: EXPERIMENTAL
Intervention: Cue exposure and response prevention
Number of subjects: 12
Study 1586360 — intervention group
Group type: COMPARATOR
Intervention: Self-control techniques
Number of subjects: 12
Study 2862933 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CSP)
Number of subjects: 48
Study 2862933 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 48
Study 31023345 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent mentor with an experimental curriculum
Number of subjects: 0
Study 31023345 — intervention group
Group type: COMPARATOR
Intervention: Parent mentor with a standard curriculum (active control)
Number of subjects: 0
Study 31023345 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 29697276 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided fine-needle aspiration (UGFNA)
Number of subjects: 1029
Study 29697276 — intervention group
Group type: COMPARATOR
Intervention: Palpation-guided fine-needle aspiration (PGFNA)
Number of subjects: 1029
Study 29697276 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided fine-needle aspiration (UGFNA) for thyroid lesions
Number of subjects: 1029
Study 29697276 — intervention group
Group type: COMPARATOR
Intervention: Palpation-guided fine-needle aspiration (PGFNA) for thyroid lesions
Number of subjects: 1029
Study 29697276 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided fine-needle aspiration (UGFNA) for head and neck lesions
Number of subjects: 1029
Study 29697276 — intervention group
Group type: COMPARATOR
Intervention: Palpation-guided fine-needle aspiration (PGFNA) for head and neck lesions
Number of subjects: 1029
Study 29697276 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided fine-needle aspiration (UGFNA) for salivary gland lesions
Number of subjects: 1029
Study 29697276 — intervention group
Group type: COMPARATOR
Intervention: Palpation-guided fine-needle aspiration (PGFNA) for salivary gland lesions
Number of subjects: 1029
Study 27212766 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoas compartment block (PCB) combined with sciatic nerve block
Number of subjects: 90
Study 27212766 — intervention group
Group type: COMPARATOR
Intervention: Adductor canal block (ACB)
Number of subjects: 90